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Abstract 
Background: Interleukin-10 (IL-10) is a powerful modulator of anti-tumor immune responses. The IL-10 promoter 
region polymorphisms are known to regulate IL-10 production, and thus are thought to be implicated in tumorigen-
esis. Recently, the roles of these polymorphisms in urologic cancer have been extensively studied, with conflicting 
results. Therefore, we conducted the present meta-analysis to better elucidate the correlations between IL-10 poly-
morphisms and urologic cancer risk.
Methods: Eligible articles were searched in PubMed, Medline, Embase, Scopus and CNKI up to May 2016. Odds ratios 
(ORs) and 95% confidence intervals (CIs) were used to detect any potential associations between IL-10 polymor-
phisms and the risk of urologic cancer.
Results: A total of 22 case–control studies including 8572 patients and 9843 controls were analyzed. The overall 
meta-analysis results showed that IL-10 −592C>A polymorphism was significantly associated with urologic cancer 
in CA versus AA (P = 0.04, OR 0.87, 95% CI 0.76–0.99) and AA versus CC+CA (P = 0.03, OR 1.15, 95% CI 1.02–1.31). 
Subgroup analyses by cancer types suggested there were significant associations between all the three investigated 
IL-10 polymorphisms and bladder cancer. However, subgroup analyses by ethnicity only detected a weak association 
between IL-10 −819C>T and Asian population.
Conclusions: Our findings suggests that IL-10 −592C>A polymorphism may implicate with urologic cancer risk. 
Besides, promoter region polymorphisms of IL-10 may serve as potential biological markers, especially for bladder 
cancer. Furthermore, IL-10 −819C>T polymorphism may contribute to urologic cancer susceptibility in Asians while all 
the three studied variants of IL-10 did not relate to Caucasian urologic cancer predisposition.
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Background
Commonly seen urologic cancers such as prostate can-
cer, renal cancer, and bladder cancer are leading causes 
of cancer-related morbidity and mortality globally (Siegel 
et al. 2014). Despite rapid advances in early diagnosis and 
surgical treatment over the past few decades, the num-
bers of new urologic cancer cases and associated deaths 
are continue to increase, making it becomes one of the 
major threats to public health worldwide (Ferlay et  al. 
2015).
To date, the exact cause of urologic cancer remains 
unclear. Certain environmental factors like smoking 
habit, heavy alcohol intake, high caloric diet and chemi-
cal dyes have been identified as potential etiological 
factors for urologic cancer. However, the fact that only 
a small portion of individuals exposed to these carcino-
genic agents ultimately develop urologic cancer suggests 
that genetic susceptibility factors may play a crucial part 
in its pathogenesis (Jiang et al. 2014).
Interleukin-10 (IL-10), encoded by the IL-10 gene 
located on chromosome 1q31–32, is a potent regulator 
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of anti-tumor immune responses (Eskdale et  al. 1997; 
Mocellin et al. 2005). As a result, certain polymorphisms 
located in the promoter region of IL-10 gene (−592C>A, 
−819C>T and −1082A>G), which regulate the expres-
sion level of IL-10 protein (Turner et al. 1997; Kingo et al. 
2005), were thought to be implicated in the pathogenesis 
of various kinds of cancers. Recently, many genetic asso-
ciation studies have been carried out to investigate the 
potential correlations between IL-10 promoter region 
polymorphisms and urologic cancer risk. However, 
results of these studies were controversial and the statis-
tical power of individual studies was insufficient. There-
fore, we conducted the present meta-analysis to better 
assess the potential associations of IL-10 genetic poly-
morphisms with the risk of urologic cancer.
Methods
Literature searching strategy
To retrieve all relevant articles, a systematic literature 
search of PubMed, Medline, Embase, Scopus and China 
National Knowledge Infrastructure (CNKI) was per-
formed using the following keywords: “Interleukin-10”, 
“IL-10”, “Interleukin 10”, “IL 10”, “polymorphism”, “vari-
ant”, “genotype”, “allele”, “prostate”, “renal”, “bladder”, 
“urinary”, “urologic”, “cancer”, “tumor”, “carcinoma”, “neo-
plasm” and “malignancy”. The initial search was con-
ducted in September 2015 and the latest update was 
performed in May 2016. In addition, the reference lists of 
all retrieved articles were reviewed manually for further 
identification of potentially relevant articles.
Inclusion criteria
The inclusion criteria for the present study were set prior 
to the literature search. Eligible studies met all the fol-
lowing conditions: (1) case–control study of unrelated 
urologic cancer patients and control subjects; (2) evalu-
ation of the associations between IL-10 polymorphisms 
(−592C>A, −819C>T and −1082A>G) and the risk of 
urologic cancer; (3) presentation of sufficient data to 
calculate the odds ratios (ORs) and corresponding 95% 
confidence intervals (CIs); (4) full text in English or Chi-
nese available. If the report was duplicated or identi-
cal patients were enrolled in two studies, only the most 
recent and complete article was included. Abstracts, fam-
ily-based association studies, case reports, case series, 
reviews, editorials, expert opinions and conference pres-
entations were intentionally excluded.
Data extraction and quality assessment
From each included studies, the following data were 
extracted: references, country of origin, ethnicity of study 
population, the number of cases and controls, types of 
urologic cancer, allelic and genotypic frequencies of IL-10 
polymorphisms in urologic cancer patients and control 
subjects, and whether the distributions of IL-10 poly-
morphisms in the control group were in accordance with 
Hardy–Weinberg equilibrium (HWE). The Newcastle-
ottawa quality assessment scale (NOS), a classical rat-
ing tool which evaluates the credibility of observational 
studies from three perspectives: selection, comparabil-
ity and exposure, was used to assess the reliability of all 
case–control studies included (Zhang et  al. 2014). This 
rating system has a score range of 0–9, and studies with a 
score of more than 7 were assumed to be of high quality. 
Two reviewers (Shi and Xie) conducted the data extrac-
tion and quality assessment independently. When neces-
sary, the reviewers wrote to the corresponding authors 
for extra information or raw data. Any discrepancies 
between two reviewers were resolved by discussion until 
reaching a consensus. The final results were reviewed by 
a senior reviewer (Li).
Statistical analysis
All data analyses were performed using Review Man-
ager Version 5.3.3 (The Cochrane Collaboration, Soft-
ware Update, Oxford, United Kingdom). HWE was 
explored with the Chi square test. ORs and 95% CIs were 
employed to evaluate potential associations between IL-
10 polymorphisms and the risk of urologic cancer. Het-
erogeneity between studies was assessed by using the Q 
test and I2 statistic. If probability value (P value) of Q test 
was less than 0.1 or I2 was greater than 50%, the random-
effect model (REM) would be adopted for analyses due 
to the existence of significant between-study heteroge-
neity. Otherwise, the fixed-effect model (FEM) would be 
applied for analyses. Subgroup analyses were performed 
based on types of cancer and ethnicity of study popula-
tion. Sensitivity analyses were carried out by omitting 
one individual study each time. Publication bias was fur-
ther evaluated with funnel plots. And a P value of 0.05 




The literature search yielded 462 results. After exclusion 
of irrelevant or duplicate articles by reading titles and 
abstracts, 39 articles were selected for further evaluation. 
Among these, a total of 22 case–control studies including 
8572 urologic cancer patients and 9843 control subjects 
met our inclusion criteria (see Fig. 1), 14/22 were about 
the IL-10 −592C>A polymorphism, 13/22 were about the 
IL-10 −819C>T polymorphism, and 20/22 were about 
the IL-10 −1082A>G polymorphism. All included stud-
ies were published between 2002 and 2016. Of these, 
there were 16 studies of prostate cancer, 4 studies of renal 
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cancer, and 2 studies of bladder cancer. All articles were 
published in English except for two in Chinese. Charac-
teristics of studies analyzing IL-10 −592C>A polymor-
phism were summarized in Table  1, characteristics of 
studies examining IL-10 −819C>T polymorphism were 
summarized in Table  2, and characteristics of studies 
investigating IL-10 −1082A>G polymorphism were sum-
marized in Table 3.    
Risk of bias in included studies
As shown in Tables 1, 2 and 3, the average NOS score of 
included studies was 7.59 (range from 7 to 8), suggest-
ing that all enrolled articles were of relatively high qual-
ity. The improper selection of controls and mismatching 
baseline characteristics of urologic cancer cases and 
control subjects (age and/or ethnicity) were the major 
sources of biases.
IL‑10 −592C>A polymorphism and urologic cancer risk
For IL-10 −592C>A polymorphism, a total of 14 stud-
ies including 5899 urologic cancer patients and 6181 
control subjects were investigated (Dluzniewski et  al. 
2012; Dwivedi et  al. 2015a, b; Eder et  al. 2007; Faupel-
Badger et al. 2008; Liu et al. 2010; VanCleave et al. 2010; 
Wang et al. 2009; Winchester et al. 2015; Xu et al. 2005; 
Zabaleta et al. 2008; Basturk et al. 2005; Cozar et al. 2007; 
Chang et  al. 2016; Chen et  al. 2013). HWE test for the 
control group of each included studies demonstrated that 
only 1 study deviated from HWE (see Table 1). In order 
to explore the association between IL-10 −592C>A poly-
morphism and urologic cancer risk, we compared distri-
bution of genotypes and alleles in every genetic model. 
For CC versus AA, CA versus AA, CA versus CC+AA, 
and AA versus CC+CA, between-study heterogene-
ity was mild, and analyses were performed with FEMs. 
Fig. 1 Flowchart of study selection for the present study
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For CC versus CA, CC versus CA+AA, and C versus A, 
REMs were selected due to severe between-study het-
erogeneity. A significant association with urologic cancer 
was found for IL-10 −592C>A polymorphism in CA ver-
sus AA (P =  0.04, OR 0.87, 95% CI 0.76–0.99) and AA 
versus CC+CA (P  =  0.03, OR 1.15, 95% CI 1.02–1.31) 
(see Figs. 2, 3).
IL‑10 −819C>T polymorphism and urologic cancer risk
A total of 13 studies with 4655 cancer cases and 6344 
healthy controls were enrolled to evaluate the asso-
ciation between IL-10 −819C>T polymorphism and 
urologic cancer risk (Dwivedi et  al. 2015a, b; Faupel-
Badger et  al. 2008; Liu et  al. 2010; VanCleave et  al. 
2010; Winchester et al. 2015; Zabaleta et al. 2008; Bas-
turk et  al. 2005; Cozar et  al. 2007; Chang et  al. 2016; 
Chen et al. 2013; Kesarwani et al. 2009; Michaud et al. 
2006; Ahirwar et  al. 2009). HWE test for the control 
group of eligible studies revealed that 4 studies violated 
HWE (see Table  2). All genetic models were tested to 
detect any differences in genotypic and allelic frequen-
cies of cases and controls. For CT versus TT, there was 
only trivial between-study heterogeneity, and FEM was 
employed for analysis. For CC versus CT, CC versus 
TT, CC versus CT+TT, CT versus CC+TT, TT versus 
CC+CT, and C versus T, between-study heterogeneity 
was obvious, and REMs were adopted for analyses. No 
significant association with urologic cancer was found 
for IL-10 −819C>T polymorphism in any genetic mod-
els (see Figs. 4, 5).
IL‑10 −1082A>G polymorphism and urologic cancer risk
Of the 20 included studies for IL-10 −1082A>G poly-
morphism, there were 7401 urologic cancer patients 
and 8437 controls (Dluzniewski et  al. 2012; Faupel-
Badger et al. 2008; Liu et al. 2010; VanCleave et al. 2010; 
Wang et al. 2009; Winchester et al. 2015; Xu et al. 2005; 
Zabaleta et al. 2008; Basturk et al. 2005; Cozar et al. 2007; 
Chang et  al. 2016; Chen et  al. 2013; Kesarwani et  al. 
2009; Michaud et  al. 2006; Ahirwar et  al. 2009; Ianni 
et al. 2013; McCarron et al. 2002; Niu 2011; Omrani et al. 
2009; Havranek et al. 2005). Deviations from HWE were 
found in 5 studies while the remaining 15 studies were 
in accordance with HWE (see Table  3). For evaluation 
of the association between IL-10 −1082A>G polymor-
phism and urologic cancer risk, frequencies of genotypes 
and alleles in cases and control subjects were compared 
in every genetic model. REMs were used for all analyses 
on account of striking between-study heterogeneity, and 
no significant association was detected between IL-10 
−1082A>G polymorphism and urologic cancer risk (see 
Figs. 6, 7).
Subgroup analysis
For IL-10 polymorphisms (−592C>A, −819C>T, 
−1082A>G) and urologic cancer risk, subgroup analy-
ses were performed by stratifying available data accord-
ing to types of cancer and ethnicity of study population. 
When data were stratified by cancer types, we found 
that IL-10 −592C>A polymorphism was significantly 
associated with bladder cancer risk in CC versus AA 
(P  =  0.002, OR 0.51, 95% CI 0.33–0.78), CA versus 
AA (P =  0.004, OR 0.64, 95% CI 0.48–0.87), CC versus 
CA+AA (P  =  0.02, OR 0.62, 95% CI 0.41–0.93), CA 
versus CC+AA (P =  0.04, OR 0.74, 95% CI 0.56–0.99), 
AA versus CC+CA (P = 0.0004, OR 1.65, 95% CI 1.25–
2.19), and C versus A (P  =  0.00001, OR 0.66, 95% CI 
0.54–0.82). Besides, IL-10 −819C>T polymorphism was 
significantly correlated with bladder cancer risk in CC 
versus CT (P  =  0.03, OR 0.71, 95% CI 0.52–0.96), CC 
versus TT (P = 0.0005, OR 0.57, 95% CI 0.41–0.78), CC 
versus CT+TT (P = 0.002, OR 0.63, 95% CI 0.47–0.84), 
and C versus T (P < 0.00001, OR 0.72, 95% CI 0.61–0.84). 
Additionally, IL-10 −1082A>G polymorphism was also 
significantly associated with the risk of bladder cancer in 
AA versus GG (P = 0.02, OR 2.00, 95% CI 1.13–3.55), AG 
versus GG (P =  0.01, OR 2.03, 95% CI 1.16–3.55), and 
GG versus AA+AG (P =  0.009, OR 0.49, 95% CI 0.28–
0.84). When data were subsequently stratified by ethnic-
ity, we observed a significant association with urologic 
cancer risk for IL-10 −819C>T polymorphism in CT ver-
sus TT (P = 0.0009, OR 0.81, 95% CI 0.69–0.95). No any 
other associations were found in subgroup analyses (see 
Tables 4, 5, 6).
Sensitivity analysis
Sensitivity analyses were carried out through removing 
one individual study each time. For IL-10 −519C>A poly-
morphism, when the study performed by Dluzniewski 
et  al. (2012), Faupel-Badger et  al. (2008) or Chen et  al. 
(2013) was excluded, the significant association with uro-
logic cancer was no longer observed in CA versus AA, 
and AA versus CC+CA. For IL-10 −819C>T polymor-
phism, when the study of Liu et  al. (2010) or Michaud 
(See figure on next page.) 
Fig. 2 Forest plots on association between IL-10 −592C>A polymorphism and urologic cancer risk. a Forest plot of CC versus CA for IL-10 −592C>A 
polymorphism and urologic cancer risk is shown. b Forest plot of CC versus AA for IL-10 −592C>A polymorphism and urologic cancer risk is shown. c 
Forest plot of CA versus AA for IL-10 −592C>A polymorphism and urologic cancer risk is shown. d Forest plot of CC versus CA+AA for IL-10 −592C>A 
polymorphism and urologic cancer risk is shown
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Fig. 3 Forest plots on association between IL-10 −592C>A polymorphism and urologic cancer risk. a Forest plot of CA versus CC+AA for IL-10 
−592C>A polymorphism and urologic cancer risk is shown. b Forest plot of AA versus CC+CA for IL-10 −592C>A polymorphism and urologic 
cancer risk is shown. c Forest plot of C versus A for IL-10 −592C>A polymorphism and urologic cancer risk is shown
(See figure on next page.) 
Fig. 4 Forest plots on association between IL-10 −819C>T polymorphism and urologic cancer risk. a Forest plot of CC versus CT for IL-10 −819C>T 
polymorphism and urologic cancer risk is shown. b Forest plot of CC versus TT for IL-10 −819C>T polymorphism and urologic cancer risk is shown. c 
Forest plot of CT versus TT for IL-10 −819C>T polymorphism and urologic cancer risk is shown. d Forest plot of CC versus CT+TT for IL-10 −819C>T 
polymorphism and urologic cancer risk is shown
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Fig. 5 Forest plots on association between IL-10 −819C>T polymorphism and urologic cancer risk. a. Forest plot of CT versus CC+TT for IL-10 
−819C>T polymorphism and urologic cancer risk is shown. b Forest plot of TT versus CC+CT for IL-10 −819C>T polymorphism and urologic cancer 
risk is shown. c Forest plot of C versus T for IL-10 −819C>T polymorphism and urologic cancer risk is shown
(See figure on next page.) 
Fig. 6 Forest plots on association between IL-10 −1082A>G polymorphism and urologic cancer risk. a Forest plot of AA versus AG for IL-10 
−1082A>G polymorphism and urologic cancer risk is shown. b Forest plot of AA versus GG for IL-10 −1082A>G polymorphism and urologic cancer 
risk is shown. c Forest plot of AG versus GG for IL-10 −1082A>G polymorphism and urologic cancer risk is shown. d Forest plot of AA versus AG+GG 
for IL-10 −1082A>G polymorphism and urologic cancer risk is shown
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Fig. 7 Forest plots on association between IL-10 −1082A>G polymorphism and urologic cancer risk. a Forest plot of AG versus AA+GG for IL-10 
−1082A>G polymorphism and urologic cancer risk is shown. b Forest plot of GG versus AA+AG for IL-10 −1082A>G polymorphism and urologic 
cancer risk is shown. c Forest plot of A versus G for IL-10 −1082A>G polymorphism and urologic cancer risk is shown
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Table 4 Subgroup analyses for IL-10 −592C>A polymorphism and urologic cancer risk
The difference in cases and controls regarding the distributions of investigated genetic polymorphisms in certain genetic model reached the statistically significant 
level, which is also less than 0.05 are indicated in italics
OR odds ratio, CI confidence interval, NA not applicable
a The number of articles
Variables P value OR (95% Cl) I‑square (%) P for the heterogeneity
Cancer type
Prostate cancer (No.a: 10)
 CC versus CA 0.99 1.00 (0.87–1.15) 49 0.05
 CC versus AA 0.51 0.94 (0.80–1.12) 22 0.25
 CA versus AA 0.37 0.93 (0.79–1.09) 0 0.85
 CC versus CA+AA 0.85 0.99 (0.85–1.14) 56 0.02
 CA versus CC+AA 0.97 1.00 (0.91–1.09) 36 0.13
 AA versus CC+CA 0.47 1.06 (0.91–1.23) 0 0.54
 C versus A 0.55 0.97 (0.89–1.07) 49 0.04
Renal cancer (No.a: 3)
 CC versus CA 0.35 1.21 (0.80–1.83) 0 0.50
 CC versus AA 0.47 1.26 (0.67–2.36) 0 0.83
 CA versus AA 0.94 0.99 (0.65–1.49) 0 0.50
 CC versus CA+AA 0.30 1.23 (0.83–1.82) 0 0.66
 CA versus CC+AA 0.40 0.87 (0.63–1.20) 0 0.39
 AA versus CC+CA 0.98 1.00 (0.67–1.47) 0 0.56
 C versus A 0.48 1.10 (0.85–1.41) 0 0.55
Bladder cancer (No.a: 1)
 CC versus CA 0.30 0.79 (0.50–1.23) NA NA
 CC versus AA 0.002 0.51 (0.33–0.78) NA NA
 CA versus AA 0.004 0.64 (0.48–0.87) NA NA
 CC versus CA+AA 0.02 0.62 (0.41–0.93) NA NA
 CA versus CC+AA 0.04 0.74 (0.56–0.99) NA NA
 AA versus CC+CA 0.0004 1.65 (1.25–2.19) NA NA
 C versus A 0.00001 0.66 (0.54–0.82) NA NA
Ethnicity
Asian (No.a: 4)
 CC versus CA 0.57 1.07 (0.84–1.37) 0 0.44
 CC versus AA 0.70 0.91 (0.55–1.50) 68 0.03
 CA versus AA 0.05 0.82 (0.68–1.00) 40 0.17
 CC versus CA+AA 0.93 0.98 (0.66–1.46) 58 0.07
 CA versus CC+AA 0.06 0.85 (0.71–1.01) 0 0.58
 AA versus CC+CA 0.38 1.15 (0.84–1.58) 66 0.03
 C versus A 0.61 0.93 (0.70–1.23) 78 0.003
Caucasian (No.a: 7)
 CC versus CA 0.89 0.99 (0.86–1.13) 52 0.06
 CC versus AA 0.31 0.87 (0.66–1.14) 0 0.58
 CA versus AA 0.37 0.88 (0.66–1.16) 0 0.75
 CC versus CA+AA 0.84 0.98 (0.80–1.20) 53 0.06
 CA versus CC+AA 1.00 1.00 (0.82–1.22) 49 0.08
 AA versus CC+CA 0.30 1.15 (0.88–1.51) 0 0.70
 C versus A 0.31 0.96 (0.88–1.04) 35 0.16
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Table 5 Subgroup analyses for IL-10 −819C>T polymorphism and urologic cancer risk
The difference in cases and controls regarding the distributions of investigated genetic polymorphisms in certain genetic model reached the statistically significant 
level, which is also less than 0.05 are indicated in italics
OR odds ratio, CI confidence interval
a The number of articles
Variables P value OR (95% Cl) I‑square (%) P for the heterogeneity
Cancer type
Prostate cancer (No.a: 8)
 CC versus CT 0.22 1.10 (0.95–1.27) 46 0.07
 CC versus TT 0.18 1.11 (0.95–1.30) 27 0.22
 CT versus TT 0.79 0.98 (0.85–1.14) 0 0.68
 CC versus CT+TT 0.27 1.09 (0.94–1.27) 56 0.03
 CT versus CC+TT 0.16 0.94 (0.86–1.03) 32 0.17
 TT versus CC+CT 0.63 0.97 (0.84–1.11) 9 0.36
 C versus T 0.44 1.05 (0.93–1.17) 58 0.02
Renal cancer (No.a: 3)
 CC versus CT 0.75 1.07 (0.71–1.59) 40 0.19
 CC versus TT 0.77 0.85 (0.30–2.46) 60 0.08
 CT versus TT 0.15 0.74 (0.49–1.11) 26 0.26
 CC versus CT+TT 0.71 0.87 (0.42–1.80) 61 0.08
 CT versus CC+TT 0.13 0.78 (0.57–1.08) 12 0.32
 TT versus CC+CT 0.08 1.42 (0.96–2.09) 50 0.13
 C versus T 0.74 0.91 (0.52–1.60) 77 0.01
Bladder cancer (No.a: 2)
 CC versus CT 0.03 0.71 (0.52–0.96) 0 0.51
 CC versus TT 0.0005 0.57 (0.41–0.78) 0 0.45
 CT versus TT 0.29 0.79 (0.51–1.23) 68 0.08
 CC versus CT+TT 0.002 0.63 (0.47–0.84) 0 0.88
 CT versus CC+TT 0.85 0.95 (0.58–1.57) 80 0.02
 TT versus CC+CT 0.05 1.42 (1.01–2.00) 55 0.14
 C versus T  <0.00001 0.72 (0.61–0.84) 21 0.26
Ethnicity
Asian (No.a: 6)
 CC versus CT 0.91 0.98 (0.72–1.35) 56 0.04
 CC versus TT 0.30 0.81 (0.55–1.21) 69 0.006
 CT versus TT 0.009 0.81 (0.69–0.95) 34 0.18
 CC versus CT+TT 0.54 0.89 (0.62–1.28) 70 0.005
 CT versus CC+TT 0.05 0.87 (0.75–1.00) 36 0.17
 TT versus CC+CT 0.09 1.23 (0.97–1.56) 60 0.03
 C versus T 0.21 0.87 (0.70–1.08) 77 0.0005
Caucasian (No.a: 4)
 CC versus CT 0.81 1.04 (0.74–1.48) 64 0.04
 CC versus TT 0.25 0.81 (0.57–1.16) 33 0.21
 CT versus TT 0.22 0.79 (0.55–1.15) 0 0.53
 CC versus CT+TT 0.89 1.03 (0.72–1.46) 68 0.02
 CT versus CC+TT 0.77 0.95 (0.69–1.31) 58 0.07
 TT versus CC+CT 0.33 1.22 (0.82–1.80) 13 0.33
 C versus T 0.97 1.01 (0.75–1.34) 68 0.02
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Table 6 Subgroup analyses for IL-10 −1082A>G polymorphism and urologic cancer risk
The difference in cases and controls regarding the distributions of investigated genetic polymorphisms in certain genetic model reached the statistically significant 
level, which is also less than 0.05 are indicated in italics
OR odds ratio, CI confidence interval
a The number of articles
Variables P value OR (95% Cl) I‑square (%) P for the heterogeneity
Cancer type
Prostate cancer (No.a: 14)
 AA versus AG 0.84 0.98 (0.82–1.17) 65 0.0007
 AA versus GG 0.66 1.07 (0.80–1.42) 79 <0.0001
 AG versus GG 0.61 1.05 (0.87–1.27) 61 0.002
 AA versus AG+GG 0.90 0.99 (0.81–1.20) 75 <0.0001
 AG versus AA+GG 0.99 1.00 (0.93–1.08) 36 0.10
 GG versus AA+AG 0.53 0.94 (0.76–1.15) 71 <0.0001
 A versus G 0.78 1.02 (0.90–1.15) 79 <0.0001
Renal cancer (No.a: 4)
 AA versus AG 0.21 1.21 (0.90–1.62) 14 0.32
 AA versus GG 0.23 1.28 (0.85–1.92) 0 0.41
 AG versus GG 0.94 1.02 (0.68–1.51) 0 0.98
 AA versus AG+GG 0.17 1.21 (0.92–1.59) 34 0.21
 AG versus AA+GG 0.38 0.88 (0.67–1.16) 0 0.67
 GG versus AA+AG 0.49 0.88 (0.61–1.27) 0 0.78
 A versus G 0.17 1.15 (0.94–1.40) 29 0.24
Bladder cancer (No.a: 2)
 AA versus AG 0.42 1.37 (0.64–2.90) 83 0.01
 AA versus GG 0.02 2.00 (1.13–3.55) 0 0.96
 AG versus GG 0.01 2.03 (1.16–3.55) 0 0.59
 AA versus AG+GG 0.23 1.46 (0.79–2.70) 76 0.04
 AG versus AA+GG 0.62 0.79 (0.32–1.97) 89 0.003
 GG versus AA+AG 0.009 0.49 (0.28–0.84) 0 0.99
 A versus G 0.09 1.49 (0.94–2.38) 68 0.08
Ethnicity
Asian (No.a: 6)
 AA versus AG 0.70 0.93 (0.65–1.33) 68 0.007
 AA versus GG 0.90 0.95 (0.39–2.30) 76 0.0009
 AG versus GG 0.74 1.14 (0.53–2.48) 67 0.01
 AA versus AG+GG 0.76 0.94 (0.64–1.39) 76 0.0008
 AG versus AA+GG 0.60 1.09 (0.79–1.51) 64 0.02
 GG versus AA+AG 0.89 0.94 (0.42–2.12) 73 0.003
 A versus G 0.99 1.00 (0.69–1.44) 83 <0.0001
Caucasian (No.a: 9)
 AA versus AG 0.62 1.07 (0.81–1.41) 59 0.02
 AA versus GG 0.54 1.15 (0.73–1.82) 78 <0.0001
 AG versus GG 0.97 1.00 (0.84–1.19) 31 0.18
 AA versus AG+GG 0.59 1.09 (0.79–1.50) 73 0.0004
 AG versus AA+GG 0.49 0.95 (0.83–1.09) 0 0.67
 GG versus AA+AG 0.40 0.89 (0.67–1.17) 57 0.02
 A versus G 0.55 1.07 (0.85–1.34) 79 <0.0001
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et  al. (2006) was removed, the null association with 
urologic cancer in CT versus TT was altered. For IL-10 
−1082A>G polymorphism, however, removing any study 
did not impact the overall results.
Publication bias
Potential publication bias was evaluated with fun-
nel plots. Visual inspection of funnel plots revealed no 
apparent asymmetry for IL-10 −592C>A, −819C>T, and 
−1082A>G polymorphisms. And these results indicated 
that significant publication bias was unlikely.
Discussion
Urologic cancer is a major public health problem. 
According to a recent survey, prostate cancer, renal 
cancer and bladder cancer altogether accounted for 
13.3% (1879,000/14090,000) new cancer cases and 7.5% 
(616,000/8201,000) cancer-related deaths worldwide in 
2012, making the urologic cancer ranked as the second 
most common group of malignancies in terms of mor-
bidity, and the third most common group of malignan-
cies in terms of mortality (Ferlay et al. 2015).
To date, the etiologies of urologic cancer are still largely 
unknown in spite of extensive studies. However, it has 
become evident recently that multiple immunomodu-
latory cytokines are implicated in the process of tumor 
genesis (Kurzrock 2001; Smyth et al. 2004). Among these 
cytokines, IL-10 is a multifunctional immunological reg-
ulator mainly produced by B cells, T cells and activated 
monocytes/marcophages. As an important modulator of 
immune responses, IL-10 can be both tumor-promoting 
and tumor-inhibiting since it has both immunosuppres-
sive and anti-angiogenic functions (Mocellin et al. 2005). 
On the one hand, the immunosuppressive property of 
IL-10 may suppress anti-tumor immune responses and 
promote tumor development. On the other hand, the 
anti-angiogenic property of IL-10 may inhibit microvas-
culature formation and tumor growth. Previous studies 
have found that serum level of IL-10 was significantly 
elevated in urologic cancer, and it was closely correlated 
with tumor progression and metastasis (Stearns et  al. 
1999; Uwatoko et al. 2002; Dwivedi et al. 2015a, b), which 
suggested that IL-10 may play a vital role in the develop-
ment of urologic cancer.
IL-10 gene is located on chromosome 1q31–32. Com-
mon promoter region polymorphisms of IL-10 gene, 
−592C>A (rs1800872), −819C>T (rs1800871) and 
−1082A>G (rs1800896) were found to influence the pro-
duction of IL-10 (Turner et  al. 1997; Kingo et  al. 2005). 
Consequently, it is biologically plausible that these poly-
morphisms may be associated with susceptibility to uro-
logic cancer.
Recently, numerous studies have tried to explore the 
potential associations between IL-10 polymorphisms 
and the risk of urologic cancer, but the results were 
contradicted. Thus, we conducted the present meta-
analysis to solve the conflict and obtain a more con-
clusive result. And our overall analyses suggested that 
IL-10 −592C>A polymorphism was significantly associ-
ated with the risk of urologic cancer in CA versus AA, 
and AA versus CC+CA. However, we failed to detect 
any significant associations with urologic cancer for IL-
10 −819C>T and −1082A>G polymorphisms in overall 
analyses. Considering the differences of carcinogenic 
mechanisms for each type of cancer and the importance 
of ethnic background in genetic investigations, stratified 
analyses were subsequently performed by categorizing 
included studies into different subgroups on the basis of 
types of cancer and ethnicity of study population. When 
data were stratified by types of cancer, we found that IL-
10 −592C>A, −819C>T and −1082A>G polymorphisms 
were all significantly associated with the risk of bladder 
cancer in certain genetic models. In addition, the A allele 
of −592C>A polymorphism and T allele of −819C>T 
polymorphism conferred an increased susceptibility to 
bladder cancer. When data were stratified by ethnicity of 
study population, a significant association with urologic 
cancer risk in Asians was detected for IL-10 −819C>T 
polymorphism in CT versus TT. No any other signifi-
cant associations between IL-10 polymorphisms and 
urologic cancer risk were observed in subgroup analyses. 
For the evaluation of the heterogeneity, we found that the 
between-study heterogeneity remained significant in sev-
eral subgroup comparisons, suggesting that differences 
in cancer type and ethnicity could not fully elucidate the 
observed inconsistent results, and other unmeasured 
characteristics of study participants may partially attrib-
ute to the heterogeneity between studies. Moreover, we 
noticed a substantial decrease of heterogeneity for IL-
10 −592C>A polymorphism when the study performed 
by Zabaleta et  al. (2008) was omitted, and that for IL-
10 −819C>T polymorphism when the study conducted 
by Chen et  al. (2013) was removed or that for IL-10 
1082A>G polymorphism when the studies of Ianni et al. 
(2013) and Niu (2011) were excluded, which suggested 
that these studies were the major sources of the observed 
heterogeneity.
This study is certainly not without limitations. Firstly, 
the number of studies investigating the associations of 
certain IL-10 polymorphisms with renal cancer or blad-
der cancer is still limited, and sample size of several 
included studies were obviously not sufficient, which 
precluded us from drawing definite conclusions. Sec-
ondly, our results were based on unadjusted estimates 
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since the majority of included studies failed to report 
baseline characteristics of individuals, such as age, sex, 
smoking status and eating habits. And lack of analyses 
adjusted for these potential confounding factors may 
affect the reliability of our results. Thirdly, although 
funnel plots revealed no apparent publication bias, 
we still could not eliminate the possibility of publica-
tion bias since only published studies were included. 
Fourthly, all included studies were published in English 
or Chinese, therefore, maybe some qualified articles in 
other languages were missed. Fifthly, genetic associa-
tions of IL-10 polymorphisms with urologic cancer may 
also be influenced by gene–gene and gene-environ-
mental interactions. It is possible that one certain poly-
morphism may be associated with the risk of urologic 
cancer, but due to interactions with multiple genes and 
environmental factors, the association would no longer 
be observed.
Conclusions
In conclusion, the current meta-analysis suggests that IL-
10 −592C>A polymorphism may implicate with urologic 
cancer risk. Besides, promoter region polymorphisms of 
IL-10 may serve as potential biological markers, espe-
cially for bladder cancer. Furthermore, IL-10 −819C>T 
polymorphism may contribute to urologic cancer sus-
ceptibility in Asians while all the three studied variants of 
IL-10 did not relate to Caucasian urologic cancer predis-
position. However, it should be pointed out that the pre-
sent results concerning renal cancer and bladder cancer 
were based on limited number of case–control studies, 
and further multi-center studies with larger sample size 
from different populations are warranted to confirm our 
results. Besides, given that immunomodulating cytokines 
play a crucial role in regulating anti-tumor immune 
responses, future investigations are needed to explore the 
potential roles of other polymorphisms of these cytokine 
genes in the occurrence and development of urologic 
cancer.
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